MicroPort CardioFlow Medtech Corp. (HK:2160)
:2160
Want to see HK:2160 full AI Analyst Report?
Top Page
MicroPort CardioFlow Medtech Corp.
(2160)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$2.50
▲(100.00% Upside)
Action:ReiteratedDate:05/03/26
The score is held down primarily by weak financial quality—widening losses, negative free cash flow, and a sharp increase in leverage—despite steady revenue growth and decent gross margins. Technicals also remain bearish with the stock below major moving averages, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Steady revenue growth
Sustained top-line growth indicates persistent demand and expanding market penetration in its core cardiovascular device markets. Over 2–6 months this supports operating leverage potential, strengthens hospital relationships, and underpins ability to scale sales & distribution investments.
Negative Factors
Widening net losses
Deep and widening losses limit internal funding for commercialization, R&D, and clinical programs. Persistently negative margins will likely require external capital or cost restructuring, constraining strategic flexibility and prolonging the path to sustainable operating profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Sustained top-line growth indicates persistent demand and expanding market penetration in its core cardiovascular device markets. Over 2–6 months this supports operating leverage potential, strengthens hospital relationships, and underpins ability to scale sales & distribution investments.
Read all positive factors
MicroPort CardioFlow Medtech Corp. (2160) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.02B
Dividend YieldN/A
Average Volume (3M)8.07M
Price to Earnings (P/E)―
Beta (1Y)1.85
Revenue Growth-4.38%
EPS GrowthN/A
CountryHK
Employees430
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.01
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.09
Price to Sales (P/S)1.34
P/FCF Ratio-13.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)HK$2.18B
MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model
Company Description
MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve Syst...
How the Company Makes Money
MicroPort CardioFlow Medtech Corp. primarily makes money by selling medical devices and related consumables used in cardiovascular procedures to hospitals, clinics, and healthcare distributors. Revenue is generally generated from (1) direct produc...
MicroPort CardioFlow Medtech Corp. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 367.53M | 399.45M | 361.56M | 336.21M | 251.03M | 200.81M |
| Gross Profit | 253.91M | 218.90M | 251.21M | 229.93M | 162.13M | 118.70M |
| EBITDA | -87.81M | -7.52M | -113.32M | -386.05M | -347.91M | -173.99M |
| Net Income | 4.85M | -131.78M | -49.45M | -471.53M | -454.39M | -183.26M |
Balance Sheet | ||||||
| Total Assets | 2.67B | 4.68B | 2.68B | 2.58B | 3.00B | 3.36B |
| Cash, Cash Equivalents and Short-Term Investments | 1.32B | 1.24B | 1.36B | 1.07B | 2.08B | 2.42B |
| Total Debt | 279.62M | 1.62B | 76.86M | 70.48M | 95.47M | 125.64M |
| Total Liabilities | 450.55M | 2.63B | 454.07M | 242.25M | 247.55M | 265.52M |
| Stockholders Equity | 2.18B | 256.23M | 2.19B | 2.33B | 2.75B | 3.10B |
Cash Flow | ||||||
| Free Cash Flow | -179.62M | -38.26M | -270.06M | -237.50M | -231.60M | -269.94M |
| Operating Cash Flow | -26.82M | -3.32M | -111.67M | -206.99M | -182.53M | -161.50M |
| Investing Cash Flow | -668.17M | 51.92M | -798.50M | -596.06M | -179.78M | -437.48M |
| Financing Cash Flow | -2.75M | 5.70M | -56.31M | -25.61M | -136.42M | 2.23B |
MicroPort CardioFlow Medtech Corp. Technical Analysis
Neutral
1.25
Price Trends
3.45
Negative
4.53
Negative
5.46
Negative
Market Momentum
-0.15
Negative
48.47
Neutral
84.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2160, the sentiment is Neutral. The current price of 1.25 is below the 20-day moving average (MA) of 3.05, below the 50-day MA of 3.45, and below the 200-day MA of 5.46, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 48.47 is Neutral, neither overbought nor oversold. The STOCH value of 84.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2160.
MicroPort CardioFlow Medtech Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$7.11B | 8.20 | 11.91% | 1.26% | 10.19% | 23.70% | |
67 Neutral | HK$6.94B | 18.02 | 9.25% | 1.88% | 29.19% | 121.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$3.92B | -6.84 | -11.27% | ― | 16.35% | 9.43% | |
49 Neutral | HK$181.71M | -0.67 | -17.38% | ― | -38.20% | -108.24% | |
43 Neutral | HK$771.77M | -0.88 | -21.05% | ― | -34.96% | 42.74% | |
42 Neutral | HK$3.02B | -1.03 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2160
MicroPort CardioFlow Medtech Corp.
2.37
-1.88
-44.24%
HK:9996
Peijia Medical Ltd.
5.84
0.27
4.85%
HK:1789
AK Medical Holdings Ltd.
6.33
0.88
16.15%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
10.81
1.77
19.58%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.08
>-0.01
-2.50%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.75
-0.64
-26.78%
MicroPort CardioFlow Medtech Corp. Corporate Events
MicroPort CardioFlow Expands Overseas Distribution Via New Connected Deals
Apr 8, 2026
MicroPort CardioFlow Medtech has entered into new 2026 international distribution framework agreements with its major shareholder MicroPort, allowing it to distribute certain cardiovascular and electrophysiology products in selected overseas regio...
MicroPort CardioFlow Revenue Rises on CRM Merger but Loss Widens in 2025
Mar 30, 2026
MicroPort CardioFlow Medtech reported 2025 revenue of USD57.0 million, up 12.6% excluding foreign exchange effects, driven by the consolidation of MicroPort CRM and a 255% surge in overseas structural heart disease sales, though gross margin slipp...
MicroPort CardioFlow Sets March 30 Board Meeting for 2025 Results and Dividend Decision
Mar 18, 2026
MicroPort CardioFlow Medtech Corporation has scheduled a board meeting for March 30, 2026, to review and approve the audited annual results for the year ended December 31, 2025. The board will also consider the publication of these results and eva...
MicroPort CardioFlow Switches Reporting Currency to U.S. Dollars
Mar 11, 2026
MicroPort CardioFlow Medtech Corporation has announced it will change the presentation currency of its consolidated financial statements from Renminbi to U.S. dollars, reflecting the growing contribution of MicroPort Cardiac Rhythm Management Limi...
MicroPort CardioFlow Completes Share Consolidation After Conditions Met
Feb 24, 2026
MicroPort CardioFlow Medtech Corporation has confirmed that its previously proposed share consolidation has become effective as of February 24, 2026, after all required conditions were satisfied. The move follows shareholder approval at an extraor...
MicroPort CardioFlow’s Next-Gen Defibrillator Wins Fast-Track Review in China
Feb 13, 2026
MicroPort CardioFlow Medtech announced that its new-generation implantable cardioverter defibrillator TILEN/EYLEN has been accepted into China’s special review pathway for innovative medical devices. The device is expected to become the firs...
MicroPort CardioFlow Wins Shareholder Approval for Share Consolidation Effective 24 February
Feb 11, 2026
Shareholders of MicroPort CardioFlow Medtech Corporation have overwhelmingly approved a share consolidation at an extraordinary general meeting held on 11 February 2026, with 100% of votes cast in favor and all directors attending either in person...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.